-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
Research & Education
Long-term GLP-1 use is an important research question because obesity is a chronic disease and trial benefits are not necessarily maintained after treatment stops.
Different studies use different durations. STEP 5 followed participants receiving semaglutide for 104 weeks. SELECT followed a cardiovascular-risk population for an average of about 40 months. These studies provide valuable evidence, but they do not answer every question about decades of exposure.
In STEP 4, participants who continued semaglutide after a run-in period had further average weight reduction, while those switched to placebo regained weight on average. STEP 5 showed sustained average reduction over two years. These findings support studying obesity treatment as chronic management rather than a brief intervention.
SELECT enrolled adults with established cardiovascular disease and overweight or obesity but without diabetes. Semaglutide reduced the trial’s composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke compared with placebo. The result should not be generalized to people who do not match the studied population.
Questions remain about very long exposure, outcomes in underrepresented groups, comparative durability, adherence, cost, and how best to preserve function and nutritional status. Post-marketing surveillance also continues after approval.
No. Treatment plans change with response, adverse effects, health status, pregnancy, access and new evidence.
No. Evidence and labeling are product-specific.
That is an individualized medical decision. Withdrawal trials show why it should be planned with the prescriber.
Read the related review of evidence after treatment withdrawal.
